Equities research analysts forecast that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.75) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Puma Biotechnology’s earnings. The lowest EPS estimate is ($4.23) and the highest is ($2.21). Puma Biotechnology posted earnings of ($1.11) per share in the same quarter last year, which would suggest a negative year over year growth rate of 147.7%. The firm is expected to report its next earnings report after the market closes on Thursday, November 9th.

According to Zacks, analysts expect that Puma Biotechnology will report full-year earnings of ($8.92) per share for the current year, with EPS estimates ranging from ($10.15) to ($8.31). For the next financial year, analysts forecast that the firm will report earnings of ($5.33) per share, with EPS estimates ranging from ($6.62) to ($3.52). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Puma Biotechnology.

Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.78).

A number of brokerages have commented on PBYI. Leerink Swann increased their target price on Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Bank of America Corporation reiterated a “buy” rating and set a $135.00 target price (up previously from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Citigroup Inc. reiterated a “buy” rating and set a $156.00 target price (up previously from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. J P Morgan Chase & Co reiterated a “buy” rating and set a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. Finally, BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $126.56.

Shares of Puma Biotechnology (NYSE:PBYI) traded up $4.85 during trading hours on Friday, reaching $131.00. The company’s stock had a trading volume of 159,036 shares.

WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/03/analysts-expect-puma-biotechnology-inc-pbyi-will-post-earnings-of-2-75-per-share.html.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total transaction of $1,501,350.00. Following the transaction, the senior vice president now owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 22.70% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Puma Biotechnology by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock worth $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter worth $162,302,000. BlackRock Inc. lifted its stake in shares of Puma Biotechnology by 5.0% during the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after purchasing an additional 86,924 shares during the period. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology during the 2nd quarter worth $50,134,000. Finally, Emerald Advisers Inc. PA lifted its stake in shares of Puma Biotechnology by 16.5% during the 3rd quarter. Emerald Advisers Inc. PA now owns 370,035 shares of the biopharmaceutical company’s stock worth $44,312,000 after purchasing an additional 52,355 shares during the period. 80.98% of the stock is currently owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.